Therapeutics in the research phase at Epic Bio include treatments for: facioscapulohumeral muscular dystrophy, targeting re-methylation the D4Z4 region to suppress DUX4 expression; Retinitis Pigmentosa 4, suppressing endogenous mutated RHO expression and producing normal RHO expression; Retinitis Pigmentosa 11, restoring PRPF3 expression to normal physiological levels; Alpha-1 Antitrypsin Deficiency, suppressing endogenous mutated A1AT expression and producing normal A1AT; and finally, heterozygous familial hypercholesterolemia, targeting pathways known to reduce cholesterol. The gene discussed is PRPF3; the disease is retinitis pigmentosa.